A 66-year-old man recently diagnosed with heart failure with preserved ejection fraction (HFpEF) is considering using a GLP-1 drug to lose weight, despite concerns about pancreatitis due to his heavy alcohol consumption.
Heart failure occurs when the heart can’t pump enough blood, causing high filling pressures that lead to fluid buildup in the body. HFpEF affects people who can still squeeze blood from the heart, but have trouble relaxing and expanding it.
Furosemide and other diuretics can alleviate symptoms, but GLP-1 drugs have been effective in managing HFpEF, especially in those with obesity. These medications not only aid weight loss but also reduce hospitalizations for heart failure.
While pancreatitis is a possible side effect of GLP-1 drugs, the risk is low, occurring in about 1 in 1,000 people taking the medication for a year. However, individuals with a history of pancreatitis may want to be cautious and consult their doctor before starting treatment.
Interestingly, studies suggest that GLP-1 drugs can reduce alcohol cravings and decrease its use in those with alcohol use disorder. The high level of alcohol consumption in this patient is toxic to the heart, but the benefits of weight loss and reduced sleep apnea might outweigh the risks.
Given his severe obesity (BMI 42.3), treatment with a GLP-1 agent could have significant benefits for his overall health. There’s also strong evidence that these medications can reduce sleep apnea in people with obesity and sleep apnea.
Source: https://eu.detroitnews.com/story/life/advice/2025/03/19/a-glp-1-agonist-can-help-reduce-weight-sleep-apnea-and-more/82222710007